Compare Stocks: QNCX, CLNN, XBIT, and LONA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$5.01 -0.2%	$5.88	$3.30 ▼ $13.50	$64.03M	0.96	61,985 shs	33,747 shs
LONA Athira Pharma	$7.06	$8.46	$3.24 ▼ $14.21	$66.29M	2.05	38,547 shs	6,581 shs
QNCX Quince Therapeutics	$23.39	$19.39	$15.10 ▼ $909.98	$22.92M	1.36	36,661 shs	35,238 shs
XBIT XBiotech	$2.23	$2.33	$2.09 ▼ $3.61	$67.99M	0.84	43,797 shs	37,802 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	-7.05%	-17.87%	-18.40%	+43.55%
LONA Athira Pharma	0.00%	-4.47%	-20.41%	-26.07%	+705,999,900.00%
QNCX Quince Therapeutics	0.00%	+31.04%	+35.75%	-12.07%	-93.04%
XBIT XBiotech	0.00%	-1.76%	-3.04%	-12.55%	-21.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$5.01 -0.2%	$5.88	$3.30 ▼ $13.50	$64.03M	0.96	61,985 shs	33,747 shs
LONA Athira Pharma	$7.06	$8.46	$3.24 ▼ $14.21	$66.29M	2.05	38,547 shs	6,581 shs
QNCX Quince Therapeutics	$23.39	$19.39	$15.10 ▼ $909.98	$22.92M	1.36	36,661 shs	35,238 shs
XBIT XBiotech	$2.23	$2.33	$2.09 ▼ $3.61	$67.99M	0.84	43,797 shs	37,802 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	-7.05%	-17.87%	-18.40%	+43.55%
LONA Athira Pharma	0.00%	-4.47%	-20.41%	-26.07%	+705,999,900.00%
QNCX Quince Therapeutics	0.00%	+31.04%	+35.75%	-12.07%	-93.04%
XBIT XBiotech	0.00%	-1.76%	-3.04%	-12.55%	-21.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	2.71	Moderate Buy	$33.25	563.67% Upside
LONA Athira Pharma	2.50	Moderate Buy	$16.00	126.63% Upside
QNCX Quince Therapeutics	2.27	Hold	$568.40	2,330.10% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNCX, CLNN, XBIT, and LONA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/15/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	QNCX Quince Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	QNCX Quince Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$80.00
6/23/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$80.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$200K	320.14	N/A	N/A	($1.62) per share	-3.09
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$26.17M	-$3.20	N/A	N/A	N/A	-25,009.70%	N/A	-137.98%	8/13/2026 (Estimated)
LONA Athira Pharma	-$105.61M	-$5.21	N/A	N/A	N/A	N/A	-381.01%	-225.74%	N/A
QNCX Quince Therapeutics	-$83.98M	-$212.40	N/A	N/A	N/A	N/A	N/A	-67.99%	8/11/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.32	N/A	N/A	N/A	N/A	-26.10%	-25.06%	N/A

Latest QNCX, CLNN, XBIT, and LONA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CLNN Clene	-$0.37	N/A	N/A	N/A	$0.06 million	N/A
8/11/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	N/A	N/A	N/A	N/A	N/A
5/14/2026	Q1 2026	CLNN Clene	-$0.6367	-$0.69	-$0.0533	-$0.69	$0.05 million	$0.02 million
5/14/2026	Q1 2026	XBIT XBiotech	$0.03	-$0.18	-$0.21	-$0.18	$7.00 million	N/A
5/11/2026	Q1 2026	QNCX Quince Therapeutics	-$26.00	-$0.59	+$25.41	$57.60	N/A	N/A
5/7/2026	Q1 2026	LONA Athira Pharma	N/A	-$1.73	N/A	-$1.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.94	1.93
LONA Athira Pharma	N/A	10.38	10.38
QNCX Quince Therapeutics	N/A	2.92	2.92
XBIT XBiotech	N/A	39.03	39.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
LONA Athira Pharma	57.12%
QNCX Quince Therapeutics	30.75%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
CLNN Clene	28.30%
LONA Athira Pharma	25.73%
QNCX Quince Therapeutics	7.10%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	12.78 million	9.16 million	No Data
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
QNCX Quince Therapeutics	60	980,000	909,000	Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

QNCX, CLNN, XBIT, and LONA Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Share Price Crosses Below 200-Day Moving Average - What's Next?

July 30, 2026 | marketbeat.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 15, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CLNN, XBIT, and LONA Company Descriptions

Clene NASDAQ:CLNN

$5.01 -0.01 (-0.20%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.17 +0.16 (+3.19%)

As of 07/31/2026 07:34 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Athira Pharma NASDAQ:LONA

$7.06 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$7.10 +0.04 (+0.50%)

As of 07/31/2026 07:34 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Quince Therapeutics NASDAQ:QNCX

$23.39 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$23.30 -0.09 (-0.38%)

As of 07/31/2026 07:38 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

XBiotech NASDAQ:XBIT

$2.23 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$2.22 0.00 (-0.22%)

As of 07/31/2026 07:34 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, CLNN, XBIT, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, CLNN, XBIT, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, CLNN, XBIT, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CLNN, XBIT, and LONA Company Descriptions

Clene NASDAQ:CLNN

Athira Pharma NASDAQ:LONA

Quince Therapeutics NASDAQ:QNCX

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, CLNN, XBIT, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, CLNN, XBIT, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, CLNN, XBIT, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CLNN, XBIT, and LONA Company Descriptions

Clene NASDAQ:CLNN

Athira Pharma NASDAQ:LONA

Quince Therapeutics NASDAQ:QNCX

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools